Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ATLANTIS trial: what clinicians have said so far
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
- NCT02566993 ↗
- Completed
- PharmaMar
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ATLANTIS yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ATLANTIS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Small-cell Lung Cancer
- Interventions
- Lurbinectedin (PM01183); Doxorubicin (DOX); Cyclophosphamide (CTX); Vincristine (VCR); Topotecan
- Arms
- Experimental Arm · Experimental
- Control Arm 1 · Active comparator
- Control Arm 2 · Active comparator
- Enrollment
- 613
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- PharmaMar
- Start
- Aug 30, 2016
- Primary completion
- Feb 24, 2020
- Results posted
- Yes
- Registry record
- NCT02566993 · updated Oct 28, 2021
Publications
linked from the registry- Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohe C, Farago AF, Lopez-Vilarino JA, Cullell-Young M, Nieto A, Vasco N, Gomez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sanchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Domine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. PubMed 36252599